LBRX · Lb Pharmaceuticals Inc
$39.00
+4.06 (+11.62%)
At close · Jul 29
Market Cap
$1.00B
Shares
28.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.94
Open$34.83
Day$34.69–38.63
52W$13.36–38.63
Avg vol 30d335K
Short int4.3M · 14.9% float · 17.6d
Short vol62%
DataSep 2025–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+14%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
85%
near high
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+53%
trailing
YTD return
+57%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
6 of 76 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.86% of float · ▼ -6.4% MoM · 17.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Squeeze score
93
high risk · 0–100
Fundamentals
EPS growth
+98%
Y/Y
Free cash flow
$-35.3M
Balance sheet
$250.2M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
85%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
6 of 76 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.86% of float · ▼ -6.4% MoM · 17.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $13
Now $35 · 85%
52-wk high $39
vs 200-day avg +44%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LBRX
this stock
Lb Pharmaceuticals Inc
|
$1.00B | +57.0% | — | — | 14.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LBRX | +13.1% | +9.5% | +52.5% | +7.7% | +57.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +14.1% | +9.5% | +45.1% | +8.5% | +48.3% |